SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending as CEO Dr. Patrick Soon-Shiong's high-profile media appearances highlight the company's revolutionary cancer treatments and AI-driven cell therapy, sparking community enthusiasm and frustration over perceived regulatory roadblocks. Investors are closely watching patient testimonials and discussing a potential short squeeze, anticipating significant market movement.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending with high community engagement ahead of the 4/20 cannabis holiday, as supporters highlight its robust culture and claim it's outperforming traditional cannabis stocks. While many advocate for its long-term potential as a "culture coin," others warn of its "pump and dump" characteristics.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is rocketing higher after exceeding Q4 earnings expectations and providing strong Q1 guidance, fueled by robust demand from hyperscale data centers for its 800G and 400G optical transceivers, with the community now debating explosive growth potential and short squeeze mechanics despite recent dilution concerns.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following its recent earnings, which highlighted significant capital expenditure plans and increasing financial leverage despite strong revenue growth, sparking a polarized debate among investors. While many express concern over the company's "debt bomb" and short-term profitability, others see the aggressive spending as a strategic "once-in-a-generation opportunity" to meet insatiable AI infrastructure demand.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending following its recent FDA approval for Revuforj in NPM1-mutated AML and being named "Best New Drug" at the Scrip Awards. The community is actively discussing the company's significant undervaluation compared to peers and strong M&A potential, particularly with partner Incyte, as investors anticipate upcoming data presentations at major conferences.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Space and Airborne Systems, Integrated Mission Systems, Communication Systems, and Aerojet Rocketdyne. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne and cyber domains. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land and sea domains. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris Technologies is trending after announcing a $1 billion Department of War investment into its Missile Solutions business, which is slated for a 2026 IPO spin-off, exciting the community and analysts who see it unlocking significant value in a booming defense sector.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending as investors weigh potential massive government contracts, including a recent "skip tracing" deal and inclusion in a $38 billion ICE detention overhaul plan, against recent volatility driven by conflicting reports and community claims of short manipulation amidst strong fundamentals.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash (DASH CRYPTO) is generating significant buzz following rumored collaborations with POL and recent integration with ACH, leading the community to anticipate a major breakout. As an "OG privacy coin" with scarce supply, investors are actively watching for Dash to follow the strong upward movement seen in Zcash amidst a broader resurgence of interest in privacy tokens.

Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry. It operates through the Drilling and Completions and Artificial Lift and Downhole segments. The Drilling and Completions segment designs, manufactures and supplies products and solutions to the drilling, subsea, coiled tubing, well stimulation and intervention markets, including applications in oil and natural gas, renewable energy, defense and communications. The Artificial Lift and Downhole segment designs, manufactures and supplies products and solutions for the artificial lift, production and infrastructure markets. The company was founded in 2005 and is headquartered in Houston, TX.

Forum Energy Technologies Inc

Forum Energy Technologies is trending due to a robust earnings report projecting significant 2026 revenue and EBITDA growth, igniting community excitement around the ambitious "FET 2030" plan and its long-term potential. Investors are actively discussing the company's aggressive share buyback program and a potential OIH ETF inclusion, positioning FET as a compelling energy play amidst a perceived bottom in the oilfield services cycle.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen (SG) is trending as its recent earnings report sparks a polarized debate among investors, with many expressing frustration over continued losses and management's strategy. However, others view the sharp price reaction as an opportunity, highlighting new initiatives like wraps and the Infinite Kitchen technology as potential catalysts for a turnaround in the competitive fast-casual market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% After Earnings Beat

BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 10.7% Higher on Better-Than-Expected Earnings...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating...

BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +1,623.08% and +172.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals Q4 Earnings Call Highlights

BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined its full-year 2025 performance and priorities for 2026 during its fourth-quarter conference call, highlighting strong growth for its hereditary...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected Earnings

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Strong Earnings...

Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Public Sector Pension Investment Board Takes $2.01 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

Public Sector Pension Investment Board purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the third quarter, according to its most recent filing with the...

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) to Release Earnings on Thursday

BioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

$BCRX Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $1.17 up 1000.00% YoY
• Reported revenue of $406.56M up 209.09% YoY
• BioCryst maintained full year 2026 global net ORLADEYO revenue guidance between $625M and $645M. BioCryst also maintained 2026 total revenue guidance between $635M and $660M.

Stocktwits

Biocryst Pharmaceuticals Inc.

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $1.17 up 1000.00% YoY
• Reported revenue of $406.56M up 209.09% YoY
• BioCryst maintained full year 2026 global net ORLADEYO revenue guidance between $625M and $645M. BioCryst also maintained 2026 total revenue guidance between $635M and $660M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Stocktwits Polls

The company announced robust Q4 2025 results with a $1.17 EPS, exceeding expectations, achieving profitability, and securing significant non-dilutive financing.

Active discussion surrounds over 40 million shares shorted and unusually high trading volume, leading many to speculate about an imminent short squeeze.

Traders are actively watching for a breakthrough past key resistance levels, with many forecasting a move towards $10 and higher targets up to $22 per share.

Optimism is building around the Navenibart program from the Astria acquisition and positive pediatric data for ORLADEYO, highlighting future growth potential.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.05	--	--	N/A
Q4 '25	$0.05	$1.12	2220.04%	BEAT
Q3 '25	$0.04	$0.06	50.75%	BEAT
Q2 '25	$0.01	$0.02	185.71%	BEAT
Q1 '25	-$0.08	$0.00	100.00%	BEAT

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest BCRX News

BCRXBiocryst Pharmaceuticals Inc.